drugset / Trial / NCT07704775
Nemolizumab for LS
NaSingle-groupOpen-labelTreatment
Summary
Patients ≥ 18 years of age with Lichen sclerosis (LS)
Timeline
- Start
- 2026-09-01
- Primary completion
- 2027-09-01
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nemolizumab | Monoclonal antibody | 30 mg | Subcutaneous |